Global Markets for Neuromodulation Devices and Implantable Infusion Pumps
Published January 2016 | 103 Pages | 42 Exhibits | Forecasts Through 2021
Order individually or subscribe and get a complete intel platform.
Overview
A rising number of patients is expected to benefit from the use of neuromodulation devices in the next 5 years according to LSI's new analysis, "Global Markets for Neuromodulation Devices and Implantable Infusion Pumps in 2016." The report discusses the major forces affecting growth in the markets for implantable infusion pumps; neuromodulation devices used for established applications such as chronic pain, sensorineural hearing loss, gastroparesis, urinary incontinence, fecal incontinence, epilepsy, major depression, Parkinson's disease, essential tremor, and dystonia; and neuromodulation systems intended for novel uses such as congestive heart failure, obstructive sleep apnea, and vision loss. Expanded indications and the adoption of neuromodulation devices for previously untapped patient populations are expected to drive growth throughout the global market, which was valued at $4.6 billion in 2015. This in-depth analysis provides detailed segmentation for neuromodulation devices and implantable infusion pumps in the U.S., Europe, and the rest of the world.
Benefits of this report:
- An analysis of the competitive landscape for neuromodulation devices and implantable infusion pumps in the U.S. and international markets;
- Quantitative metrics including patient populations, the number of systems sold, and revenues; and
- Detailed forecasts covering the period from 2014-2021.
Companies Covered
Advanced Bionics/SonovaBoston Scientific
Cerbomed
CerebralRx
Cochlear
Codman & Shurtleff (Johnson & Johnson)
Flowonix
ImThera
Inspire Medical Systems
LivaNova (formerly Cyberonics)
MED-EL
Medtronic
Neurelec
Neuronetics
NeuroPace
NeuroSigma
Nurotron
St. Jude Medical
Table of Contents
1. EXECUTIVE SUMMARY 1.1 The United States 1.2 Europe 1.3 Asia-Pacific and the Rest of the World 1.4 Competitive Analysis Exhibit 1-1: Global Market Forecast for Neuromodulation Devices and Implantable Infusion Pumps, 2014-2021 Exhibit 1-2: Global Market Forecast, Neuromodulation Devices and Implantable Infusion Pumps by Region, 2014-2021 Exhibit 1-3: U.S. Market Forecast for Neuromodulation Devices & Implantable Infusion Pumps by Product Type, 2014-2021 Exhibit 1-4: European Market Forecast for Neuromodulation Devices & Implantable Infusion Pumps by Product Type, 2014-2021 Exhibit 1-5: AP & ROW Market Forecast for Neuromodulation Devices & Implantable Infusion Pumps by Product Type, 2014-2021 Exhibit 1-6: Global Supplier Shares for Neuromodulation Devices & Implantable Infusion Pumps, 2014 & 2015 2. PRODUCTS AND COMPANIES 2.1 Neuromodulation Devices 2.1.1 Deep Brain Stimulation 2.1.2 Cochlear and Middle Ear Implants for Sensorineural Hearing Loss 2.1.3 Gastrointestinal Stimulation 2.1.4 Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea 2.1.5 Retinal Stimulation 2.1.6 Sacral Nerve 2.1.7 Spinal Cord 2.1.8 Trigeminal Nerve 2.1.9 Vagus Nerve 2.1.10 Novel Neuromodulation Targets 2.2 Implantable Infusion Pumps Exhibit 2-1: Neuromodulation Devices and Implantable Infusion Pumps Exhibit 2-2: Selected Neuromodulation Devices in 2016 Exhibit 2-3: Selected Implantable Infusion Pumps in 2016 3. NEUROMODULATION & IMPLANTABLE INFUSION PUMPS: GLOBAL MARKET ANALYSIS 3.1 Procedure Volumes and Market Forecasts: Neuromodulation Devices by Region 3.1.1 The United States 3.1.1.1 Spinal Cord Stimulation for Pain 3.1.1.2 Sensorineural Hearing Loss 3.1.1.3 Gastroenterological and Urological 3.1.1.4 Epilepsy 3.1.1.5 Deep Brain Stimulation 3.1.1.6 Obstructive Sleep Apnea 3.1.1.7 Competitive Analysis 3.1.2 Europe 3.1.2.1 Spinal Cord Stimulation for Pain 3.1.2.2 Sensorineural Hearing Loss 3.1.2.3 Gastroenterological and Urological 3.1.2.4 Epilepsy 3.1.2.5 Deep Brain Stimulation 3.1.2.6 Obstructive Sleep Apnea 3.1.2.7 Congestive Heart Failure 3.1.3 Asia-Pacific and the Rest of the World 3.1.3.1 Spinal Cord Stimulation for Pain 3.1.3.2 Sensorineural Hearing Loss 3.1.3.3 Gastroenterological and Urological 3.1.3.4 Epilepsy 3.1.3.5 Deep Brain Stimulation 3.1.4 Competitive Analysis for Markets Outside of the U.S. 3.2 Procedure Volumes and Market Forecasts: Implantable Infusion Pumps by Region Exhibit 3-1: Global Market Forecast for Neuromodulation Devices and Implantable Infusion Pumps, 2014-2021 Exhibit 3-2: Global Market Forecast, Neuromodulation Devices and Implantable Infusion Pumps by Region, 2014-2021 Exhibit 3-3: Global Market Forecast for Neuromodulation Devices by Product Type, 2014-2021 Exhibit 3-4: Global Market Forecast for Neuromodulation Devices by Region, 2014-2021 Exhibit 3-5: U.S. Market Forecast for Neuromodulation Devices by Product Type, 2014-2021 Exhibit 3-6: U.S. Market Forecast for Spinal Cord Stimulation Devices, 2014-2021 Exhibit 3-7: U.S. Market Forecast for Sensorineural Hearing Loss Neuromodulation Devices, 2014-2021 Exhibit 3-8: U.S. Market Forecast for Gastroenterological and Urological Neuromodulation Devices, 2014-2021 Exhibit 3-9: U.S. Market Forecast for Neuromodulation Devices Used to Treat Epilepsy, 2014-2021 Exhibit 3-10: U.S. Market Forecast for Deep Brain Stimulation Devices, 2014-2021 Exhibit 3-11: U.S. Market Forecast for Neuromodulation Devices Used for Obstructive Sleep Apnea, 2014-2021 Exhibit 3-12: U.S. Supplier Shares for Neuromodulation Devices, 2014 & 2015 Exhibit 3-13: European Market Forecast for Neuromodulation Devices by Product Type, 2014-2021 Exhibit 3-14: European Market Forecast for Spinal Cord Stimulation Devices, 2014-2021 Exhibit 3-15: European Market Forecast for Sensorineural Hearing Loss Neuromodulation Devices, 2014-2021 Exhibit 3-16: European Market Forecast for Gastroenterological and Urological Neuromodulation Devices, 2014-2021 Exhibit 3-17: European Market Forecast for Neuromodulation Devices Used to Treat Epilepsy, 2014-2021 Exhibit 3-18: European Market Forecast for Deep Brain Stimulation Devices, 2014-2021 Exhibit 3-19: European Market Forecast for Neuromodulation Devices Used for Obstructive Sleep Apnea, 2014-2021 Exhibit 3-20: European Market Forecast for Neuromodulation Devices Used for Congestive Heart Failure, 2014-2021 Exhibit 3-21: AP & ROW Market Forecast for Neuromodulation Devices by Product Type, 2014-2021 Exhibit 3-22: AP & ROW Market Forecast for Spinal Cord Stimulation Devices, 2014-2021 Exhibit 3-23: AP & ROW Market Forecast for Sensorineural Hearing Loss Neuromodulation Devices, 2014-2021 Exhibit 3-24: AP & ROW Market Forecast for Gastroenterological and Urological Neuromodulation Devices, 2014-2021 Exhibit 3-25: AP & ROW Market Forecast for Neuromodulation Devices Used to Treat Epilepsy, 2014-2021 Exhibit 3-26: AP & ROW Market Forecast for Deep Brain Stimulation Devices, 2014-2021 Exhibit 3-27: OUS Supplier Shares for Neuromodulation Devices, 2014 & 2015 Exhibit 3-28: Global Market Forecast for Implantable Infusion Pumps by Region, 2014-2021 Exhibit 3-29: U.S. Market Forecast for Implantable Infusion Pumps, 2014-2021 Exhibit 3-30: U.S. Supplier Shares for Implantable Infusion Pumps, 2014 & 2015 Exhibit 3-31: European Market Forecast for Implantable Infusion Pumps, 2014-2021 Exhibit 3-32: AP & ROW Market Forecast for Implantable Infusion Pumps, 2014-2021 Exhibit 3-33: OUS Supplier Shares for Implantable Infusion Pumps, 2014 & 2015 4. COMPANIES COVERED *Detailed profiles for companies in bold. 4.1 Advanced Bionics/Sonova 4.2 Boston Scientific 4.3 Cerbomed 4.4 CerebralRx 4.5 Cochlear 4.6 Codman & Shurtleff (Johnson & Johnson) 4.7 Flowonix Medical 4.8 ImThera 4.9 Inspire Medical Systems 4.10 LivaNova 4.11 MED-EL 4.12 Medtronic 4.13 Neurelec 4.14 Neuronetics 4.15 NeuroPace 4.16 NeuroSigma 4.17 Nurotron 4.18 St. Jude Medical
Ready to get started?
We help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.
